Sycamore Partners Has Nared Deal to Sell Boots

The pharmacy chain could be sold to the Weston family for $9 billion in a deal expected within weeks.

Updated on Sept. 30, 2026 in Healthcare

Isometric editorial illustration showing five colorful, geometric building blocks cleanly separated from a single central architectural base.
Sycamore Partners is nearing a $9 billion deal to sell the pharmacy chain Boots to the Weston family, following a strategy to break up the company into five distinct business units. AI Illustration. Upload story photo >

Live Poll

Do you trust private equity firms to manage retail chains like Boots in the public interest?

Sycamore Partners is nearing an agreement to sell the pharmacy chain Boots to the Weston family for $9 billion. This move comes after the firm split the former Walgreens business into five distinct units to facilitate the sale of non-core assets.

Why it matters

The sale reflects a strategic effort to offload business segments following the 2025 acquisition of Walgreens, which had suffered from a significant decline in market value prior to the buyout.

The proposed sale price for the Boots chain stands at $9 billion, representing a significant portion of the $10 billion valuation assigned to the entire Walgreens acquisition in 2025. Sycamore Partners previously restructured the company into five distinct units.

The players

Sycamore Partners

This private equity firm specializes in retail and consumer-focused investments and holds a diverse portfolio of brands.

Boots

This prominent pharmacy and health and beauty retailer operates a vast network of stores, primarily throughout the United Kingdom.

Weston family

This prominent business family maintains significant international investments in retail and real estate sectors.

Walgreens

This major pharmacy chain operates thousands of retail locations across the United States.

The details

Sycamore Partners split the broader Walgreens entity into five units to streamline the divestment of assets deemed non-core. The firm originally took the company private in 2025 to address a sharp decline in its public market value.

Timeline

  1. Sycamore Partners took Walgreens private in 2025.

  2. The potential sale was reported on September 30, 2026.

  3. The deal is expected to be completed in the coming weeks.

Market Landscape

The sale of Boots follows the pattern established by the 2025 Walgreens privatization and corporate restructuring, which sought to unlock value through segment separation. This divestment marks a tactical execution of the firm's broader plan to offload non-core assets to rival competitors.

Shoppers and employees may see changes in corporate strategy or operational focus as Boots moves under new ownership. Customers should monitor for potential adjustments in loyalty programs or store-level services following the ownership transition.

The takeaway

Divestment strategies often follow major acquisitions as private equity firms work to refine their portfolios. Investors and consumers should note that breaking up large corporations into smaller units is a common tactic used to maximize asset value.

Further reading

For more on industry shifts, explore the Healthcare section.

Live Poll

Do you trust private equity firms to manage retail chains like Boots in the public interest?